Abiant Selected to Present at 2009 ADNI Investigators Meeting
Deerfield, ILLINOIS - - April 26, 2009 - - Work co-authored by members of Abiant and the New York University School of Medicine was presented on April 26 at the 2009 Alzheimer's Disease Neuroimaging Initiative (ADNI) Investigators Meeting in Seattle, Washington. The presentation, titled "Regional Cerebral Glucose Metabolism at Baseline Predicts Symptom Onset in Normal ADNI Subjects and Correlates to Disease Progression", focused on the results of analyses performed using the neuroimaging scans in 250 patients in the ADNI database.
The results of this work showed that glucose metabolism levels declines in select regions of the brain as subjects decline from Normal to Mild Cognitive Impairment stages and later Alzheimers Disease. Since glucose metabolism is a primary source of energy for the brain, measurement of glucose utilization in various brain regions using positron emission tomography (PET) imaging provides a powerful way to "see", or measure, where activity in the brain is declining. One of the earliest regions of decline is the hippocampus, a structure involved in encoding new memories. Even in Normal subjects, decreased glucose metabolism activity can be seen well before the subjects show symptoms.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the ADNI website.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers of drug effects and disease progression. The imaging information, which includes biochemical, functional, and structural measurements, is intended to accelerate or reduce risk of decision making in both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,” "achieve," and "enable." There are a number of important factors that could cause Abiant's results to differ materially from those indicated by these forward-looking statements.
Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030